In the News

Ann Pokalsky and Patricia Wilczynski Brozek give presentations at AIPLA’s webinar: “Focus on North America: Patent and Trademark Protection in Canada, the U.S. and Mexico.”

Ann Pokalsky and Patricia Wilczynski Brozek give presentations at AIPLA’s webinar: “Focus on North America: Patent and Trademark Protection in Canada, the U.S. and Mexico.” On April 15, 2020, Ann Pokalsky and Patricia Wilczynski Brozek, presented during AIPLA’s live webinar: “Focus on North America: Patent and Trademark Protection in Canada, the U.S. and Mexico.” They…

Read More

AIPLA webinar : “Inequitable Conduct after Regeneron”

AIPLA webinar : “Inequitable Conduct after Regeneron” Ann Pokalsky, a member of AIPLA’s Online Programs Committee, has coordinated a webinar entitled “Inequitable Conduct after Regeneron” to take place Thursday, June 7, 2018, at 12:30-2:00 p.m., ET. The webinar will be presented by Tom Irving, of Finnegan Henderson Farabow Garret & Dunner, LLP and David Hricik,…

Read More

U.S. Supreme Court Rules Inter Partes Review Proceedings do not Violate Article III or Seventh Amendment of the Constitution

U.S. Supreme Court Rules Inter Partes Review Proceedings do not Violate Article III or Seventh Amendment of the Constitution In a much-anticipated decision, the Supreme Court on Tuesday, April 24, 2018, held that inter partes review (IPR) proceedings do not violate Article III or the Seventh Amendment of the Constitution. Oil States Energy Services, LLC v. Greene’s Energy…

Read More

CAFC Rules Petitioner has Burden of Proof

CAFC Rules Petitioner has Burden of Proof to Demonstrate Unpatentability of Patent Owner’s Amended Claims in an Inter Partes Review On October 4, 2017, the U.S. Court of Appeals for the Federal Circuit (CAFC) sitting en banc, ruled that the petitioner has the burden of persuasion with respect to demonstrating unpatentability of amended claims proposed by…

Read More

Update on Regeneron Pharmaceuticals Inc. v. Merus N.V.

Update on Regeneron Pharmaceuticals Inc. v. Merus N.V. On Tuesday, September 12, 2017, as expected, Regeneron Pharmaceuticals Inc. petitioned  the Court of Appeals for the Federal Circuit (CAFC) for a rehearing en banc of its panel decision rendered in Regeneron Pharmaceuticals Inc. v. Merus N.V., 864 F3d 1343, 123 USPQ2d 1469 (Fed. Cir. 2017). On September 26, 2017, Washington…

Read More